Please assess the completion status of the following clinical trial:

Trial Title: BAY88-8223, Does Response Study in HRPC Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Histologically/cytologically confirmed adenocarcinoma of the prostate~* Patient is hormone refractory with evidence of progressive disease:~  * Patient must be maintained on androgen ablation therapy with LHRH agonist or have undergone orchiectomy~ * Patient's testosterone level is required to be equal to or below 50 ng/dl~ * Patients in which flutamide, nilutamide, megestrol acetate, polyestradiol phosphate, aminoglutethimide, and ketoconazole, has been recently withdrawn must demonstrate progression of disease and be at last 4 weeks beyond the discontinuation of such agents; for bicalutamide 6 weeks is required~ * Increase in PSA levels in two consecutive measurements with at least one week apart, demonstrating an increase over the reference (nadir) value, and with the final PSA \>/= 5 ng/ml~    * A reference PSA (nadir) value must be measured at least 4 weeks after the discontinuation of flutamide, nilutamide, megestrol acetate, polyestradiol phosphate, aminoglutethimide, and ketoconazole, and at least 6 weeks after discontinuation of bicalutamide~   * If the third PSA value is lower than the second value, the patient could still be eligible, provided a fourth measurement obtained at least 1 week after the third PSA value, is grater than the second PSA value and \>/= 5 ng/ml~* Multifocal (\>1) skeletal metastases confirmed by bone scintigraphy within 6 weeks~* Bone pain with a score of at least 2 on BPI average pain, despite adequate use of analgesics, that correlates with areas of increased uptake (osteoblastic activity) on bone scintigraphy~* Performance status: ECOG 0-2 or Karnofsky \>/= 60%~* Life expectancy: At least 3 months~* Age more than 40 years~* Laboratory requirements:~  * Neutrophil count \>/= 1,5 x 109/L~ * Platelet count \>/= 100 x109/L~ * Hemoglobin \> 95 g/L~ * Bilirubin within normal institutional limits~ * ASAT and ALAT \<2,5 times upper limit of normal (ULN)~* The patient is willing and able to comply with the protocol (including maintenance of patient diary, completion of pain assessment forms), and agrees to return to the hospital for follow-up visits and examinations~* The patient has been fully informed about the study and has signed the informed consent form~Exclusion criteria~* Has received an investigational drug within 4 weeks before the administration of radium-223, or is scheduled to receiving one during the study period~* Has received chemo-, immunotherapy, or external radiotherapy within the last 4 weeks prior to entering the study, or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier~* Has received prior hemibody external radiotherapy~* Has received systemic radiotherapy with strontium-89, samarium-153, rhenium-186 or rhenium 188 for the treatment of bony metastases within the last year prior to inclusion~* Has started treatment with bisphosphonates less than 3 months prior to administration of study drug~* Patients experiencing hormone withdrawal syndrome, or are \</= 4 weeks post withdrawal of antiandrogen therapy (6 weeks for bicalutamide)~* Patients who have started steroids or changed to treatment with steroids within the last 4 weeks prior to administration of radium-223~* Has other clinically significant or symptomatic disease, which might interfere with the assessment of bone pain, e.g. spinal cord compression, compression or infiltration of a neural plexus, nerve root or peripheral nerves~* Other currently active (relapse within the last 3 year) malignancy (except non-melanoma skin cancer), or known brain or visceral metastases dominating the clinical picture of the patient~* Other serious illness or medical condition:~  * any uncontrolled infection~ * cardiac failure Classification III or IV (New York Heart Association)~ * Crohn disease or Ulcerative colitis~ * known bone fracture within 8 weeks

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radium-223 dichloride (Xofigo, BAY88-8223)-5kBq/kg (Type: EXPERIMENTAL): Each patient received a single injection of radium-223 , based on the randomised dose level (5kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator.
- Radium-223 dichloride (Xofigo, BAY88-8223)-25 kBq/kg (Type: EXPERIMENTAL): Each patient received a single injection of radium-223 , based on the randomised dose level (25kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator.
- Radium-223 dichloride (Xofigo, BAY88-8223)-50 kBq/kg (Type: EXPERIMENTAL): Each patient received a single injection of radium-223 , based on the randomised dose level (50kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator.
- Radium-223 dichloride (Xofigo, BAY88-8223)-100 kBq/kg (Type: EXPERIMENTAL): Each patient received a single injection of radium-223 , based on the randomised dose level (100kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).